spacer
home > pmps > summer 2008 > rfid to the rescue
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

RFID to the Rescue

During the development process of new therapeutic approaches, multi-phase clinical research studies (clinical trials) are the last hurdle to overcome. Hence clinical trials represent one of the crucial steps in the development of a new drug. In view of increasing competition, rising cost pressures and, above all, the need to bring new products to market as quickly as possible, the current process of clinical trial supply management harbours inefficiencies, which can be eliminated by innovative RFID-based technologies.

‘TIME TO MARKET’ IS CRUCIAL

The total costs of developing a new drug or treatment up to the point of approval can amount to as much as US$ 1 billion. Typically, a new drug will have been subjected to around 10 years of stringent preclinical testing before entering the first of a total of three clinical trial phases. Nonetheless, according to information published by the FDA in 2004, a new drug has merely an eight per cent chance of achieving final approval and thus being brought to market. One of the reasons for this is the fact that results obtained in animal tests can be applied to humans only to a limited extent: around 90 per cent of substances found to be safe with lab animals fail the test of subsequent clinical trials on humans.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Guido Moosmann is Business Development Director RFID at Schreiner MediPharm, one of the major divisions of Schreiner Group based in Oberschleissheim near Munich, Germany. Guido has extensive academic and industry experience in the field of RFID technologies. He is the author and co-author of various studies and books on source tagging and RFID standards.
spacer
Guido Moosmann
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

3P Biopharmaceuticals and Nordic Nanovector have extended partnership for Betalutin® late stage manufacturing for B-cell non-Hodgkin lymphoma (NHL) treatment

The non-Hodgkin lymphoma (NHL) is a cancer that starts in white blood cells called lymphocytes, which are part of the body’s immune system
More info >>

White Papers

ECCRT

ECCRT

The European Centre for Clinical Research Training (ECCRT) is a professional clinical research training provider focusing on the transfer of implementable knowledge for the day-to-day activities of our participants whether being new to the industry, starters on the job, or seasoned professionals. Our mission is to facilitate Clinical Research professionals to excel in their job for the benefit of patients. We aim to achieve this by providing clinical research professionals with competencies to develop new therapies for patients quicker & more efficiently, without jeopardizing quality and safety.
More info >>

 
Industry Events

FlyPharma Europe

22-23 October 2019, Copenhagen, Denmark

The FlyPharma Conference Europe 2019 is aimed at forward-thinking individuals and businesses that are ready to uncover the potential in their pharma supply chain. The event offers an interactive platform to discuss current and future challenges within pharma and cargo, with topics including market trends, cold chain innovations, latest regulatory demands, security technology, and how to encourage collaboration between supply chain players. There will be plenty of networking opportunities, including a complimentary evening networking event, where delegates can meet and catch up with senior and executive pharma and cargo professionals – gaining strong, new industry contacts and building on existing ones.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement